BioSpace News Archive

Navrogen, Inc., a biopharmaceutical company specialized in developing therapies for cancer and immune-related disorders, announces today a publication describing new criteria for antibody-drug conjugate (ADC) development and preclinical efficacy of NAV-001 ADC against mesothelin-expressing tumor types.

Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the “Company” or “Sona”), a nanotechnology company developing pre-clinical Targeted Hyperthermia Therapy for colorectal cancer, is pleased to announce the election as chair of the board

Justera Health Ltd. (CSE: VTAL) (OTCQB: SCRSF) (formerly ScreenPro Security Inc.) (“Justera” or the “Company”) is pleased to announce that it has successfully changed its name to “Justera Health Ltd.”

Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the “Company” or “Inspira Technologies”), a company aiming to revolutionize acute respiratory care, announced today its financial results for the first quarter ended March 31, 2023.

Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) cell therapy for critical care indications, announced on Monday, May 15th financial results for the three months ended March 31, 2023 and provided a business update.

Copernicus Therapeutics, Inc., today announced preliminary data, in collaboration with Northeastern University and Tufts University, that demonstrated plasmid GDNF DNA nanoparticles (pGDNF NPs) delivered intranasally bypass the blood-brain barrier to allow gene expression in brain cells, which ultimately results in a reduction in drug-seeking behaviors in rats.

BiomeSense, a biotech company unlocking the vast health benefits of the microbiome through novel “smart bathroom” hardware technology and advanced bioinformatics, announced the close of its oversubscribed $3 million funding round.

Plandai Biotechnology is pleased to announce a comprehensive rebranding initiative following the successful completion of its share exchange agreement with ByoPlanet, LLC.

GT Medical Technologies, Inc. announced receipt of the 1,000th order for GammaTile Therapy.

AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved RINVOQ® (upadacitinib) for the treatment of adults with moderately to severely active Crohn’s disease who have had an inadequate response or intolerance to one or more TNF blockers.